Survival in patients with glioblastoma at a first progression does not correlate with isocitrate dehydrogenase (IDH)1 gene mutation status.

ABSTRACT:

Backgrounds

Mutations in the isocitrate dehydrogenase (IDH)1 gene are favourable prognostic factors in newly diagnosed diffuse gliomas, whereas it remains controversial in the recurrent glioblastoma setting.

Methods

A total of 171 patients with newly diagnosed glioblastoma, either 'primary' glioblastoma or 'secondary' glioblastoma, treated at Kyorin University Hospital or Japanese Red Cross Medical Center from 2000 to 2015 were included. Patients with confirmed IDH1 status and O6-methylguanine-DNA methyltransferase promoter methylation status were retrospectively analysed for overall survival from the initial diagnosis (n = 147) and after the first progression (n = 122).

Results

IDH1 mutation but not IDH2 was noted in 19 of 147 patients with glioblastoma (12.9%). In p

SUBMITTER: Tabei Y 

PROVIDER: S-EPMC7767982 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature